Obesity pharmacotherapy: What is next?

被引:43
作者
Colon-Gonzalez, Francheska [1 ,2 ]
Kim, Gilbert W. [1 ,3 ]
Lin, Jieru E. [1 ]
Valentino, Michael A. [1 ]
Waldman, Scott A. [1 ,4 ]
机构
[1] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Waldman Lab, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Mol Pharmacol & Struct Biol Program, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA
关键词
Obesity; Anti-obesity drugs; Appetite; Metabolism; GLUCAGON-LIKE PEPTIDE-1; FOOD-INTAKE; PANCREATIC-POLYPEPTIDE; WEIGHT-LOSS; NEUROPEPTIDE-Y; BODY-WEIGHT; INSULIN THERAPY; ENERGY-INTAKE; GUT HORMONE; LEPTIN;
D O I
10.1016/j.mam.2012.10.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The increase in obesity in the Unites States and around the world in the last decade is overwhelming. The number of overweight adults in the world surpassed 1 billion in 2008. Health hazards associated with obesity are serious and include heart disease, sleep apnea, diabetes, and cancer. Although lifestyle modifications are the most straightforward way to control weight, a large portion of the population may not be able to rely on this modality alone. Thus, the development of anti-obesity therapeutics represents a major unmet medical need. Historically, anti-obesity pharmacotherapies have been unsafe and minimally efficacious. A better understanding of the biology of appetite and metabolism provides an opportunity to develop drugs that may offer safer and more effective alternatives for weight management. This review discusses drugs that are currently on the market and in development as anti-obesity therapeutics based on their target and mechanism of action. It should serve as a roadmap to establish expectations for the near future for anti-obesity drug development. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:71 / 83
页数:13
相关论文
共 136 条
  • [1] 7TM-Pharma, 2011, OB
  • [2] 7TM-Pharma, 2011, TM30339 7TMPHARM
  • [3] PHARMACOKINETICS OF PANCREATIC POLYPEPTIDE IN MAN
    ADRIAN, TE
    GREENBERG, GR
    BESTERMAN, HS
    BLOOM, SR
    [J]. GUT, 1978, 19 (10) : 907 - 909
  • [4] DISTRIBUTION AND RELEASE OF HUMAN PANCREATIC POLYPEPTIDE
    ADRIAN, TE
    BLOOM, SR
    BRYANT, MG
    POLAK, JM
    HEITZ, P
    BARNES, AJ
    [J]. GUT, 1976, 17 (12) : 940 - 944
  • [5] HUMAN DISTRIBUTION AND RELEASE OF A PUTATIVE NEW GUT HORMONE, PEPTIDE-YY
    ADRIAN, TE
    FERRI, GL
    BACARESEHAMILTON, AJ
    FUESSL, HS
    POLAK, JM
    BLOOM, SR
    [J]. GASTROENTEROLOGY, 1985, 89 (05) : 1070 - 1077
  • [6] AEterna-Zentaris, 2011, AETERMA ZEMT PROD DE
  • [7] Role of leptin in the neuroendocrine response to fasting
    Ahima, RS
    Prabakaran, D
    Mantzoros, C
    Qu, DQ
    Lowell, B
    MaratosFlier, E
    Flier, JS
    [J]. NATURE, 1996, 382 (6588) : 250 - 252
  • [8] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
    Amori, Renee E.
    Lau, Joseph
    Pittas, Anastassios G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02): : 194 - 206
  • [9] AMRI, 2011, OB MCH 1 ANT
  • [10] Amylin, 2011, AM TAK VOL SUSP CLIN